Gene regulation by BCL3 in a cervical cancer cell line
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20974051
PII: file/6020/fb2010a0025.pdf
Knihovny.cz E-resources
- MeSH
- Down-Regulation MeSH
- HeLa Cells MeSH
- Humans MeSH
- RNA, Small Interfering genetics metabolism MeSH
- Cell Line, Tumor MeSH
- Uterine Cervical Neoplasms genetics metabolism MeSH
- B-Cell Lymphoma 3 Protein MeSH
- Proteins genetics metabolism MeSH
- Proto-Oncogene Mas MeSH
- Proto-Oncogene Proteins genetics metabolism MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- RNA Interference MeSH
- Oligonucleotide Array Sequence Analysis MeSH
- Gene Expression Profiling MeSH
- STAT3 Transcription Factor genetics metabolism MeSH
- Transcription Factors genetics metabolism MeSH
- Up-Regulation MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- BCL3 protein, human MeSH Browser
- RNA, Small Interfering MeSH
- MAS1 protein, human MeSH Browser
- B-Cell Lymphoma 3 Protein MeSH
- Proteins MeSH
- Proto-Oncogene Mas MeSH
- Proto-Oncogene Proteins MeSH
- STAT3 Transcription Factor MeSH
- Transcription Factors MeSH
BCL3 is a putative proto-oncogene deregulated in haematopoieitic and solid tumours. It has been suggested that its oncogenic effects could be mediated, at least in part, by inducing proliferation and inhibiting cell death. To provide more insight into the mediators of these effects, we used an unbiased approach to analyse the mRNA expression changes after knocking-down BCL3 using specific shRNAs. One hundred eighty genes were up-regulated and sixtynine genes were down-regulated after knocking down BCL3. Function analyses showed enrichment in genes associated with cellular growth and proliferation, cell death and gene expression. We found that STAT3, an important oncogene in human cancer, was the central node of one of the most significant networks. We validated STAT3 as a bona fide target of BCL3 by additional interference RNA and in silico analyses of previously reported lymphoma patients.